XML 88 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Net loss per common share (Tables)
 6 Months Ended
Jun. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following potentially dilutive securities were excluded from the computation of diluted weighted average common shares outstanding due to their anti-dilutive effect:
As of June 30,
20242023
Shares to be issued upon conversion of Convertible Notes15,939,216 15,416,667 
Vested and unvested stock options
8,943,175 9,307,846 
Restricted stock units
16,765,889 10,602,771 
Warrants
8,362,270 8,362,270 
Total anti-dilutive securities excluded from EPS computation (1)
50,010,550 43,689,554 
(1) Total anti-dilutive securities exclude CVRs which are settleable in cash, additional Xeris Biopharma shares, or a combination, at the election of the Company.